chen, chenyan – page 12 – eisai china lnc.-开元体育官网下载手机版

 chen, chenyan – page 12 – eisai china lnc.-开元体育官网下载手机版

entries by

eisai china inc. awarded great suzhou best employer for second consecutive years

on august 22, the “2018 great suzhou best employer award ceremony” was held at suzhou jinji lake international convention center. eisai china inc. (eci) has been accredited great suzhou best employer for second consecutive years. the “best employer” selection project has been organized for 5 years since 2013. it is now the most influential and appealing event in suzhou for employer brand selection. this project has successfully attracted the participation of over one thousand enterprises and the attention of millions of employees and has become an annual ceremony for the display of employer brands in suzhou. 

tokyo august 17, 2018 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth n.j., u.s.a., known as msd outside of the united states and canada, announced today that the u.s. food and drug administration (fda) approved the kinase inhibitor lenvima® (lenvatinib mesylate) for the first-line treatment of patients with unresectable hepatocellular carcinoma (hcc). this approval was based on results from reflect (study 304), where lenvima demonstrated a proven treatment effect on overall survival (os) *1 by statistical confirmation of non-inferiority, as well as statistically significant superiority and clinically meaningful improvements in progression-free survival (pfs) *2 and objective response rate (orr) *3 when compared with sorafenib in patients with previously untreated unresectable hcc. this is the second approval of lenvima for use in the treatment of hcc following approval in japan earlier this year, and the first new systemic therapy to be approved in the u.s. for the first-line treatment of unresectable hcc in approximately 10 years.

tokyo & kenilworth, n.j., july 31, 2018 – eisai co., ltd. and merck & co., inc. kenilworth, n.j., u.s.a. (nyse:mrk), known as msd outside the united states and canada, announced today that the u.s. food and drug administration (fda) granted breakthrough therapy designation for lenvima® (generic name: lenvatinib mesylate), the orally available kinase inhibitor discovered by eisai, in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy keytruda® (generic name: pembrolizumab) for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high (msi-h)/proficient mismatch repair (pmmr) endometrial carcinoma (ec) who have progressed following at least one prior systemic therapy.

eisai signs collaboration agreement for anti-obesity agent lorcaserin in china to cy biotech

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the united states: belviq®, product name for once-daily formulation in the united states: belviq xr®, “lorcaserin”) in china (including hksa and chinese macao) to cy biotech (headquarters: taipei, chinese taiwan, “cyb”).

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib) (headquarters: cambridge, massachusetts, united states, ceo: michel vounatsos, “biogen”) announced detailed results from the phase ii study (study 201) with ban2401, an anti-amyloid beta (aβ) protofibril antibody, in 856 patients with early alzheimer‘s disease as part of session dt-01 “recent developments in therapeutics (presentation number: dt-01-07) at the alzheimer’s association international conference (aaic) 2018 being held in chicago, illinois, united states on july 25. this abstract was accepted for late breaking oral presentation at aaic.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announces today that a total of 13 presentations highlighting results from a phase ii clinical study (study 201) of the anti-amyloid beta (aβ) protofibril antibody ban2401 and a phase ii clinical study (study 202) of the oral bace (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: e2609) in addition to the latest data on its alzheimer‘s disease / dementia pipeline including anti-aβ antibody aducanumab, will be given at the alzheimer’s association international conference (aaic) 2018, in chicago from july 22 to 26, 2018. ban2401, elenbecestat and aducanumab are being jointly developed by eisai and biogen inc. (headquarters: cambridge, massachusetts, united states, “biogen”).

abbvie and eisai announce the launch of humira® for subcutaneous injection 20 mg syringe 0.2 ml, a new pediatric formulation of humira®

tokyo, june 21, 2018 – abbvie gk (headquarters: tokyo, president: james feliciano, “abbvie”) and eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that humira® for subcutaneous injection 20 mg syringe 0.2 ml, a new pediatric formulation of humira ® (generic name: adalimumab [recombinant], “humira”), a fully human anti-tnf-α monoclonal antibody formulation, has been launched today after being listed in the national health insurance reimbursement price list on june 15.

join hands to make a win-win situation — eisai china launches its first liver reserve function testing device in china market

june 20, 2018, eisai china region held a grand launching campaign for its rk-1000 model a, a new generation of icg clearance meter, in jw marriott hotel shanghai. the staff from merchants department and partners in china region got together witnessing the company’s first clinical diagnosis device hitting the market. the device will be promoted together with indocyanine green for injection, a product of eisai (liaoning) pharmaceutical co. ltd. this is an attempt of eisai china to expend its business to a new field, which will enrich its product line in the treatment of hepatic diseases such as hepatic carcinoma, hepatic injury, hepatic encephalopathy, and etc., greatly improve its market competitiveness and provide better solution of diagnosis and treatment for both doctors and patients in china.

tokyo jun 4, 2018 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada), announced today that results from presentations of new data and analyses of lenvima® (lenvatinib), an orally available kinase inhibitor discovered by eisai, in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy, keytruda® (pembrolizumab), in four different tumor types: unresectable hepatocellular carcinoma (hcc) (abstract #4076), squamous cell carcinoma of the head and neck (scchn) (abstract #6016), advanced renal cell carcinoma (rcc) (abstract #4560), and advanced endometrial carcinoma (ec) (abstract #5596 and abstract #5597). the data are included in presentations at the 54th annual meeting of the american society of clinical oncology (asco) in chicago from june 1-5. lenvima and keytruda are not approved for use in combination in any cancer types today.

网站地图